BIOCARDIA

Our therapeutic development strategies incorporate personalized and precision medicine to enable the patients most likely to benefit from these therapies to receive them. Therapies are also delivered in a local targeted fashion to the tissue most in need to maximize their therapeutic window for patient benefit. For our three cardiovascular indications, local targeted delivery is performed with our proprietary Helix™ transendocardial biotherapeutic delivery system (Helix system). This is a therapeutic-enabling platform for minimally invasive targeted delivery of biologic agents to the heart. The Helix system empowers a seamless transition from bench to commercialization for partners. Navigation within the heart using the Helix system is enabled by our proprietary Morph® DNA steerable introducer products... We are developing cellular and cell-derived therapeutics for the treatment of unmet cardiovascular and pulmonary diseases.

Also known as: BIOCARDIA, INC.

Primary location: Sunnyvale United States